Clinical experience with everolimus (Certican): A summary

Transplantation

Volumn 79, Issue 9 SUPPL., 2005, Pages

  Ponticelli, Claudio ^a,b  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^b NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; CYCLOSPORIN A; EVEROLIMUS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ARTHRALGIA; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG MONITORING; DRUG POTENTIATION; DRUG TOLERABILITY; EDEMA; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; INFECTION; LYMPHOCELE; MOUTH ULCER; NEPHROTOXICITY; PRIORITY JOURNAL; SHORT SURVEY;

EID: 18544363571     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200505153-00008     Document Type: Short Survey

References (11)

1. Olyaei AJ, de Mattos AM, Bennett WM. Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr Opin Crit Care 2001; 7: 384.
2. Pilmore HL, Dittmer ID. Calcineurin inhibitor nephrotoxicity: reduction in dose results in marked improvement in renal function in patients with coexisting chronic allograft nephropathy. Clin Transplant 2002; 16: 191.
3. Weir MR, Ward MT, Blahut SA, et al. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 2001; 59: 1567.
4. Oppenheimer F, Aljama P, Asensio Peinado C, et al. The impact of donor age on the results of renal transplantation. Nephrol Dial Transplant 2004; 19: iii11.
5. Ponticelli C. Renal transplantation 2004: where do we stand today? Nephrol Dial Transplant 2004; 19: 2937.
6. Certican summary of product characteristics. Novartis Pharma AG, Basel, Switzerland.
7. Schuurman H-J, Cottens S, Fuchs S, et al. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation 1997; 64: 32.
8. Nashan B, Curtis J, Ponticelli C, et al. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study. Transplantation 2004; 78: 1332.
9. Kovarik JM, Kaplan B, Tedesco Silva H, et al. Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. Transplantation 2002; 73: 920.
10. Lorber M, Ponticelli C, Whelchel J, et al. Therapeutic drug monitoring for everolimus in kidney transplant recipients based on the exposure-efficacy and safety modelling of 12-month data. Clinical Transplantation 2004; 19: 145.
11. Vitko S, Tedesco H, Eris J, et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004; 4: 626.